The XIII International AIDS Conference took place in Durban, South Africa from July 9-14, 2000. The Body was pleased to provide coverage of this important conference. Covering the conference for The Body were some of the leading HIV specialists in the United States. They have helped put in perspective the hundreds of reports coming out of Durban. Among the doctors providing coverage were Cal Cohen, M.D., Ann Collier, M.D., Judith Currier, M.D., Judith Feinberg, M.D., Alvan Fisher, M.D., and Pablo Tebas, M.D.
12,000 people from all over the world attended the conference, including an immense assortment of people involved in HIV/AIDS care or prevention. Those attending included scientists and clinicians, health care workers, public health agencies, people living with AIDS, AIDS non-governmental organizations (NGOs), AIDS services organizations (ASOs) and the media. Since 1985, the International AIDS Conference has taken place regularly -- it now takes place every two years.
The theme of this year's conference was "Break The Silence," which the conference coordinators refer to as the urgent need to break the silence on equal access to treatment and care; improved and ongoing prevention of HIV transmission; governmental and private sector support of HIV education and resources; human rights; access of appropriate and meaningful information to all sectors and ensuring a supportive environment for people living with HIV/AIDS (PWA) in society.
This theme was particularly appropriate this year as Sub-Saharan Africa continues to have the largest number of people living with HIV -- each day about 1,500 people in South Africa are infected with HIV. Thus one focus of this year's conference in South Africa was the crucial need for response to the epidemic in South Africa and other developing countries around the world.
Funding for this conference coverage at The Body was provided, in part, by unrestricted educational grants from Agouron Pharmaceuticals, Inc., Bio-Technology Group Corp., DuPont Pharmaceuticals Company, Glaxo Wellcome, Ortho Biotech Inc., and Roxane Laboratories, Inc.
| The Body's Conference Summaries |
Day One
Monday,
July 10 | Day Two
Tuesday,
July 11 | Day Three
Wednesday,
July 12 | Day Four
Thursday,
July 13 |
Opening Ceremony
(Sunday, July 9)
Plenary: The Jonathan Mann Memorial Lecture
(Sunday, July 9)
Anemia and HIV
Men Who Have Sex With Men
Patient Adherence to Antiretroviral Therapies -- I
Animal Models -- Interventions
Symposium: The Science of HIV/AIDS -- Evolution & Impact
Symposium: Management of Drug Resistance
Male Circumcision: An Ignored Intervention
|
Plenary Session: Living with AIDS
Post-Exposure Prophylaxis (PEP)
New Antivirals/Targets
Adherence to Antiretroviral Therapy -- Why So Low?
The Prevalence of Hypogonadism in HIV-Infected Patients Receiving HAART
Behavioral Predictors and Outcomes of HAART
Attempts at Simplifying Treatment Regimens
ARV Clinical Trials -- II
More on Salvage Studies
Safety and Efficacy of Abacavir and Efavirenz
Mitochondrial Toxicity
Debate: Affordable Drugs, Antiretroviral Therapy
Reverse Transcriptase Mutation Patterns from ZDV-Naïve Subjects Failing d4T-Containing Regimens
Pharmacokinetics of Amprenavir in Combination with Efavirenz or Delavirdine in HIV-Infected Children
Therapeutic Drug Monitoring of Amprenavir Combined with Ritonavir as Salvage Therapy in HIV-1-Infected Patients
HIV-Related Malignancies
|
Post Sexual-Exposure Prophylaxis with HAART After Sexual Assaults
Sustained Virologic Suppression in Subjects Switched from Protease Inhibitors to Nevirapine
The Combination of Ritonavir and Amprenavir in Salvage Regimens Overcomes Clinically Multiple-Drug-Resistant HIV
Hormones and Body Composition
New Antiretrovirals -- I
Switching Antiretroviral Regimens
Co-Infection of HIV and Hepatitis Viruses
Emergence of Drug Resistance in the Treatment-Naïve Population
Lipodystrophy and Quality of Life
Switching Protease Inhibitor to Nevirapine Leads to Reversal of Hyperlipidemia and Lipodystrophy
The Cost of Managing Abnormal Fat Distribution and Metabolic Abnormalities in France
Clinical Trials of Antiretroviral Therapy
Responses to Salvage Combination Therapy with Efavirenz in Patients with HIV Who Have Failed Antiretroviral Therapy with a Protease Inhibitor
Prospective, Multicenter Study of ddI + Hydroxyurea + Efavirenz + Protease Inhibitor Salvage Therapy
Virologic Response to Indinavir, Efavirenz, and Adefovir Among Patients Failing Nelfinavir
Management of HIV Disease in Real Life
Abacavir, Lamivudine, and Efavirenz
Nelfinavir vs. Indinavir
Response to Salvage with Efavirenz: Implications for Sequencing Antiretroviral Therapy
Incidence and associations of fatigue in HIV-infected persons
|
Symposium: Issues in Antiretroviral Treatment
Development of Resistance to Stavudine (d4T) in Patients Who Fail on d4T-Containing Regimens
Patient Adherence with Twice-Daily Dosing of Nelfinavir Equivalent to NNRTIs When Given in Combination with Dual NRTIs
Study of Adherence to HAART in a Sample of HIV-Infected Patients
Lipodystrophy: Definition and Treatment
Self-Efficacy: Predictor of Adherence to Antiretroviral Medications
Hepatitis C and HIV Co-Infection: Clinical Aspects
Management of Drug Resistance
Does Optimism about HIV Treatment Lead to Riskier Sexual Behavior?
Forty-Eight-Week Analysis of Patients Receiving T-20 as a Component of Multi-Drug Salvage
Drug Interruptions, Holidays and Pauses: An Overview of Outcomes
Short Cycle Intermittent HAART: A Pilot Study
The Swiss-Spanish Intermittent Trial (SSITT)
The One-Year Safety and Efficacy Data of the HIVNET 012 Trial
Genotypic Resistance Analysis in Women Participating in PACTG 316 with HIV-1 Subtype E Subjects Using LIPA Assay
Drug Resistance in Mother-to-Child HIV Transmission
Bones and Nails
Closing Ceremony
|
